Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
13.45
+0.48 (3.70%)
At close: Aug 13, 2025, 4:00 PM
13.45
0.00 (0.00%)
Pre-market: Aug 14, 2025, 8:00 AM EDT
Syndax Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 professional analysts, the 12-month price target for Syndax Pharmaceuticals stock ranges from a low of $17 to a high of $56. The average analyst price target of $36.58 forecasts a 171.97% increase in the stock price over the next year.
Price Target: $36.58 (+171.97%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Syndax Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 7 | 7 | 8 | 8 | 8 | 9 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 11 | 11 | 11 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $46 → $51 | Strong Buy | Maintains | $46 → $51 | +279.18% | Aug 5, 2025 |
| BTIG | BTIG | Strong Buy Maintains $43 → $56 | Strong Buy | Maintains | $43 → $56 | +316.36% | Aug 5, 2025 |
| UBS | UBS | Strong Buy Maintains $37 → $35 | Strong Buy | Maintains | $37 → $35 | +160.22% | Jul 15, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $18 | Strong Buy | Initiates | $18 | +33.83% | Jul 10, 2025 |
| Scotiabank | Scotiabank | Hold Maintains $16 → $17 | Hold | Maintains | $16 → $17 | +26.39% | May 6, 2025 |
Financial Forecast
Revenue This Year
126.61M
from 23.68M
Increased by 434.67%
Revenue Next Year
264.14M
from 126.61M
Increased by 108.62%
EPS This Year
-3.94
from -3.72
EPS Next Year
-2.73
from -3.94
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 161.9M | 391.7M | 461.3M | ||
| Avg | 126.6M | 264.1M | 358.9M | ||
| Low | 81.3M | 212.6M | 239.3M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 583.9% | 209.3% | 74.6% | ||
| Avg | 434.7% | 108.6% | 35.9% | ||
| Low | 243.5% | 67.9% | -9.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -3.52 | -1.68 | -1.04 | ||
| Avg | -3.94 | -2.73 | -1.81 | ||
| Low | -4.25 | -3.25 | -2.09 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.